📊 PRGO Key Takeaways
Is PERRIGO Co plc (PRGO) a Good Investment?
Perrigo is experiencing severe financial distress with massive operating losses (-$1.1B) and negative net income (-$1.4B) despite maintaining a decent 35.1% gross margin, indicating fundamental operational challenges. High leverage (1.23x Debt/Equity) with $3.6B long-term debt and only $531.6M cash creates refinancing risk, particularly given declining revenue (-2.8% YoY) and deteriorating returns (ROE -48.6%, ROA -16.7%). While positive free cash flow ($145.1M) and healthy liquidity ratios provide some near-term cushion, the sustainability of operations is questionable without evidence of path to profitability.
Why Buy PERRIGO Co plc Stock? PRGO Key Strengths
- Positive free cash flow of $145.1M despite accounting losses indicates operational cash generation
- Decent gross margin of 35.1% suggests underlying business units have pricing power
- Strong liquidity position with current ratio of 2.76x and quick ratio of 1.63x provides near-term flexibility
PRGO Stock Risks: PERRIGO Co plc Investment Risks
- Massive operating loss of $1.1B and net loss of $1.4B with deterioration of 723% YoY indicates severe operational distress
- High debt burden of $3.6B with limited cash ($531.6M) creates refinancing risk and constrains financial flexibility
- Revenue declining at 2.8% YoY in pharmaceutical sector suggests competitive pressure and market share loss with no growth trajectory
Key Metrics to Watch
- Operating margin trend and path to profitability
- Revenue growth stabilization and market share trends
- Debt refinancing activities and leverage ratio progression
PERRIGO Co plc (PRGO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 3.4% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.76x current ratio provides a solid financial cushion.
PRGO Profit Margin, ROE & Profitability Analysis
PRGO vs Healthcare Sector: How PERRIGO Co plc Compares
How PERRIGO Co plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is PERRIGO Co plc Stock Overvalued? PRGO Valuation Analysis 2026
Based on fundamental analysis, PERRIGO Co plc shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
PERRIGO Co plc Balance Sheet: PRGO Debt, Cash & Liquidity
PRGO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: PERRIGO Co plc's revenue has grown significantly by 12% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.09 indicates the company is currently unprofitable.
PRGO Revenue Growth, EPS Growth & YoY Performance
PRGO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.0B | $2.0M | $-0.05 |
| Q2 2025 | $1.1B | $2.0M | $-0.06 |
| Q1 2025 | $1.0B | $2.0M | $0.01 |
| Q3 2024 | $1.1B | $2.0M | $0.10 |
| Q2 2024 | $1.1B | $2.0M | $0.04 |
| Q1 2024 | $1.1B | $2.0M | $0.01 |
| Q3 2023 | $1.1B | -$2.4M | $0.10 |
| Q2 2023 | $1.1B | -$2.4M | $0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
PERRIGO Co plc Dividends, Buybacks & Capital Allocation
PRGO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for PERRIGO Co plc (CIK: 0001585364)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRGO
What is the AI rating for PRGO?
PERRIGO Co plc (PRGO) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRGO's key strengths?
Claude: Positive free cash flow of $145.1M despite accounting losses indicates operational cash generation. Decent gross margin of 35.1% suggests underlying business units have pricing power.
What are the risks of investing in PRGO?
Claude: Massive operating loss of $1.1B and net loss of $1.4B with deterioration of 723% YoY indicates severe operational distress. High debt burden of $3.6B with limited cash ($531.6M) creates refinancing risk and constrains financial flexibility.
What is PRGO's revenue and growth?
PERRIGO Co plc reported revenue of $4.3B.
Does PRGO pay dividends?
PERRIGO Co plc pays dividends, with $159.3M distributed to shareholders in the trailing twelve months.
Where can I find PRGO SEC filings?
Official SEC filings for PERRIGO Co plc (CIK: 0001585364) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRGO's EPS?
PERRIGO Co plc has a diluted EPS of $-10.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PRGO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, PERRIGO Co plc has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PRGO stock overvalued or undervalued?
Valuation metrics for PRGO: ROE of -48.6% (sector avg: 15%), net margin of -33.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PRGO stock in 2026?
Our dual AI analysis gives PERRIGO Co plc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PRGO's free cash flow?
PERRIGO Co plc's operating cash flow is $238.5M, with capital expenditures of $93.4M. FCF margin is 3.4%.
How does PRGO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -33.5% (avg: 12%), ROE -48.6% (avg: 15%), current ratio 2.76 (avg: 2).